In addition, several in vitro studies demonstrated that several cancer cell lines incorporate gemcitabine mostly via the hENT1 and hCNT1 transporters and that treatment of cells with nucleoside transport inhibitors NBMPR or dipyridamole markedly reduced the sensitivity to gemcitabine (Mackey et al, 2003). This evidence concerns the gene SLC28A1 and cancer.